Surprisingly, the treatment of AML cells with mebendazole, an anti-helminth drug routinely used in the clinic for children with parasitic infections, has shown anti-leukemia activity via c-MYB inhibition in both MLL-rearranged and non-rearranged cells (Walf-Vorderwülbecke et al., 2018). The gene discussed is KMT2A; the disease is leukemia.